Počet záznamov: 1
talidomid
SYS d013792 LBL 00000nz--a2200000o--4500 005 20250606214344.4 008 990101|||anznnbabn-----------|-a|a------ 040 $b slo $a DNLM $d BA006 $d BA006 065 $a D02.241.223.805.810.800 065 $a D03.383.621.808.800 065 $a D03.633.100.513.750.750 066 $a 01 $c 03 150 $a talidomid $x AA $x AD $x AE $x AG $x AI $x AN $x BL $x CF $x CH $x CL $x CS $x EC $x HI $x IM $x IP $x ME $x PD $x PK $x PO $x RE $x SD $x ST $x TO $x TU $x UR $2 slo 550 $7 sllk_us_auth*d007166 $Y Immunosuppressive Agents $w P $a imunosupresíva 550 $7 sllk_us_auth*d007917 $Y Leprostatic Agents $w P $a antileprotiká 550 $7 sllk_us_auth*d013723 $Y Teratogens $w P $a teratogény 550 $7 sllk_us_auth*d020533 $Y Angiogenesis Inhibitors $w P $a inhibítory angiogenézy 680 9-
$i A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action. $2 eng 750 -2
$a Thalidomide $2 eng 980 $x M
Počet záznamov: 1